| 翻訳と辞書 |
Kohzoh Imai
Kohzoh Imai (今井浩三, Kohzoh Imai, born January 1, 1948) is a Japanese physician and oncologist specializing in molecular diagnosis and novel medical treatment of cancer. He is well known for the discovery of a melanoma-related antigen (later, it is called, Chondroitin Sulfate Proteoglycan-4 (CSPG4)) by producing a monoclonal antibody.〔Imai K, Ng A-K, Ferrone S. Characterization of monoclonal antibodies to human melanoma-associated antigens. J Natl Cancer Inst, 66(3): 489-496, 1981. doi: 10.1093/jnci/66.3.489〕 In addition, he produced monoclonal antibodies against CEA or ICAM-1 and found out they are usable in the diagnosis and the pathological analysis.〔Imai K, Moriya Y, Fujita H, Tsujisaki M, Kawaharada M, Yachi A. Immunologic characterization and molecular profile of carcinoembryonic antigen detected by monoclonal antibodies. J Immunol, 132(6): 2992-2997, 1984. http://www.ncbi.nlm.nih.gov/pubmed/6202769〕
He is a former professor and president of Sapporo Medical University. He was a Council Member of Science Council of Japan (The 20th and 21st term). Also he was invited by Their Majesties the Emperor and Empress to their spring garden party in 2009. He was a professor and the director at Research Hospital, The Institute of Medical Science, the University of Tokyo in 2010, a recipient of the Medal of Honor with Purple Ribbon in 2013, and currently a project professor at the University of Tokyo and the director of (Kanagawa Cancer Center Research Institute ) in 2014 to present.
==Contribution==
Imai discovered three kinds of protein tyrosine phosphatase (PTP) genes having the function of controlling the signal transduction of cancer cells.〔Adachi M, Miyachi T, Sekiya M, Hinoda Y, Yachi A, Imai K. Structure of the human LC-PTP (HePTP) gene: similarity in genomic organization within protein-tyrosine phosphatasegenes. Oncogene, 9: 3031-3035, 1994. http://europepmc.org/abstract/med/8084610〕〔Adachi M, Fischer EH, Ihle H, Imai K, Jirik F, Neel B, Pawson T, Shen S-H, Thomas M, Ullrich A, Zhao Z. Mammalian SH2-containing protein tyrosine phosphatase. Cell, 85: 15, 1996.〕 His research on the treatment with siRNA targeting PRDM14 molecule expressed in cancer cells is soon to be clinically applied to patients in Japan.〔http://www.nikkei.com/article/DGXLZO81465710Z21C14A2TJM000/〕〔Nishikawa N, Toyota M (Corresponding author), Suzuki H, Homma T, Fujikane T, Ohmura T, Nishidate T, Ohe-Toyota M, Maruyama R, Sonoda T, Sasaki Y, Urano T, Imai K, Hirata K, Tokino T. Gene amplification and overexpression of PRDM14 in breast cancer. Cancer Res, 67: 9649-9657, 2007. doi: 10.1158/0008-5472.CAN-06-4111〕 Further, he developed the diagnostic method of a digestive tract cancer utilizing a methylation of genes expressed in cancer cells.〔Suzuki H, Watkins DN, Jair K-W, Schuebel KE, Markowitz SD, Chen W-D, Pretlow TP, Y ang B, Akiyama Y, Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG, Baylin SB. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet, 36(4): 417-422, 2004. doi:10.1038/ng1330〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Kohzoh Imai」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|